CORRECTING and REPLACING Forest Laboratories, Inc. Announces Commercial Availability of VIIBRYD(TM) in Pharmacies

Please replace the release with the following corrected version due to multiple revisions.

The corrected release reads:

FOREST LABORATORIES, INC. ANNOUNCES COMMERCIAL AVAILABILITY OF VIIBRYD(TM) IN PHARMACIES

New Treatment for Major Depressive Disorder in Adults Now Available in Pharmacies

Forest Laboratories, Inc. (NYSE: FRX) announced today that VIIBRYD(TM) (vilazodone HCl) tablets is now available at pharmacies throughout the United States. VIIBRYD is a prescription medicine indicated for the treatment of adults with Major Depressive Disorder (MDD).

The U.S. Food and Drug Administration (FDA) approved VIIBRYD as a new molecular entity on January 21, 2011, making it the first and only approved selective serotonin reuptake inhibitor (SSRI) and 5HT1A receptor partial agonist. The mechanism of the antidepressant effect of VIIBRYD is not fully understood but is thought to be related to its enhancement of serotonergic activity in the central nervous system (CNS) through selective inhibition of serotonin reuptake. Vilazodone is also a partial agonist at serotonergic 5HT1A receptors; however, the net result of this action on serotonergic transmission and its role in vilazodone’s antidepressant effect are unknown.

The efficacy of VIIBRYD as a treatment for MDD was established in two 8-week, multicenter, randomized, double-blind, placebo-controlled studies of 861 adult patients, 436 of whom received VIIBRYD, and who met the criteria for MDD. In these studies, patients were titrated over two weeks to a dose of 40 mg of VIIBRYD once daily with food. VIIBRYD was superior to placebo in the improvement of depressive symptoms as measured by the mean change from baseline (95% confidence interval) to week 8 in the Montgomery-Asberg Depression Rating Scale (MADRS) total score of -3.2 (-5.2, -1.3) and -2.5 (-4.4, -0.6) for Studies 1 and 2, respectively.

VIIBRYD was demonstrated to be safe in clinical studies. In the placebo-controlled, pivotal studies, the most commonly observed adverse reactions in VIIBRYD-treated patients were diarrhea, nausea, vomiting and insomnia. No single adverse event led to discontinuation of treatment in greater than 1% of patients. Overall, 7.1% of the patients who received VIIBRYD discontinued treatment due to an adverse reaction, compared with 3.2% of placebo-treated patients. VIIBRYD has not been associated with any clinically important changes in laboratory test parameters including liver function tests, ECG including QT interval or vital signs. In addition, VIIBRYD had no effect on body weight as measured by mean change from baseline in the 8-week studies. Among the common adverse reactions (≥2%) related to sexual function with VIIBRYD compared to placebo were decreased libido (4% vs

Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From May 2024 to Jun 2024